X

Trial Profile

A Randomized Phase 2b Trial Evaluating Clinical Outcomes of Inhaled Sargramostim in High-risk Patients With Mild-moderate COVID-19

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Dec 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sargramostim (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use
Acronyms SCOPE
Sponsors Partner Therapeutics

Most Recent Events

20 Dec 2023 Results presented in the Partner Therapeutics Media Release.
20 Dec 2023 According to Partner Therapeutics media release, Open Forum Infectious Diseases published results from this trial. These data were also presented at IDWeek 2023.
22 Feb 2022 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com